✦ LIBER ✦
A phase II trial of a non-myeloablative regimen combining in vivo T cell depletion with an anti-CD52 monoclonal antibody (alemtuzumab), and chemotherapy with fludarabine and melphalan prior to a related or unrelated hematopoietic stem cell transplantation
✍ Scribed by H. Castro-Malaspina; E. Papadopoulos; J. Ann; P. Miguel Angel; Y. James; H. Katherine; B. Farid; P. Vinot; S. Trudy; K. Nancy; V. Marcel; D. Hanna; O. Richard
- Book ID
- 116277724
- Publisher
- Elsevier Science
- Year
- 2004
- Tongue
- English
- Weight
- 51 KB
- Volume
- 10
- Category
- Article
- ISSN
- 1083-8791
No coin nor oath required. For personal study only.